Samuel R Saks
CIK 1365615 · Chief Medical Officer · last filed 2021-02-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
JAZZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94304
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTGX | Chief Medical Officer | 14,000 | $125.50 | $1.76M | $0 | 5 | 2021-02-26 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 214,190 | — | — | $0 | 5 | 2019-06-24 |
| TNXP | Director | 0 | $2.58 | $0 | $150.0K | 12 | 2018-06-13 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | 5,099 | — | — | $0 | 7 | 2016-05-20 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Chief Development Officer | 0 | — | — | $26.1K | 3 | 2015-05-06 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Director | 0 | — | — | $0 | 4 | 2010-10-28 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Director | — | — | — | $0 | 1 | 2009-07-07 |
| JAZZ | Chief Executive Officer | 358,868 | $234.93 | $84.31M | $384.1K | 8 | 2009-01-23 |
Recent Filings · Page 5 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-05-29 | Trubion Pharmaceuticals, Inc (TRBN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-19 | JAZZ | Grant (A) | +8,793 | $0 | EDGAR |
| 2007-12-03 | JAZZ | Other (J) | +590 | $7.8K | EDGAR |
| 2007-11-15 | JAZZ | Buy (P) | +4,900 | $65.6K | EDGAR |
| 2007-11-14 | JAZZ | Buy (P) | +23,738 | $318.5K | EDGAR |
| 2007-09-17 | — | Grant (A) | — | $0 | |
| 2007-06-06 | JAZZ | Conv (C) | +79,817 | $0 | EDGAR |
| 2007-05-30 | Trubion Pharmaceuticals, Inc (TRBN) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).